RELAPSED NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tackle tough lymphoma
Disease control OngoingThis early-phase trial is testing the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 23 adults will participate. The goal is to find a …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Supercharged immune cells take on tough B-Cell cancers in early trial
Disease control OngoingThis early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a quick radiation boost make CAR T-Cell therapy work better for lymphoma?
Disease control OngoingThis early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC